Phosphatidylserine (PS) is a naturally occurring phospholipid found in virtually every cell in the body, with its highest concentration in the brain and adrenal cortex — two of the most metabolically active tissues in the stress response. As a structural component of cell membranes, PS supports membrane fluidity and the signaling architecture that governs how cells communicate under stress. In the context of BHRT practice, its most clinically relevant action is its ability to modulate the hypothalamic-pituitary-adrenal (HPA) axis, making it a valuable adjunct for patients presenting with the high-cortisol, alarm-phase pattern of HPA axis dysfunction.
The mechanism by which PS exerts its cortisol-modulating effect is unusually precise. Rather than acting broadly at the adrenal gland level, PS appears to work upstream at the pituitary, blunting the release of adrenocorticotropic hormone (ACTH) in response to stress signals. This means it reduces cortisol output by dampening the neuroendocrine signal that triggers it — a mechanistically
meaningful distinction that makes PS well-suited to patients whose cortisol excess is driven by chronic HPA hyperactivation rather than primary adrenal pathology. It also helps explain why PS does not appear to suppress cortisol indiscriminately; in subjects with normal cortisol levels, the blunting effect is far less pronounced than in those who are chronically stressed.
The clinical evidence base for PS is one of the stronger ones in adrenal nutraceuticals. A placebo-controlled study published in the European Journal of Clinical Pharmacology found that 800 mg/day of PS for 10 days significantly blunted both ACTH and cortisol responses to physical stress in healthy men. A subsequent dose-response study confirmed that 400 mg/day reduced cortisol by 16% and 800 mg/day by approximately 25–30% following exercise challenge. Importantly, a randomized, placebo-controlled trial using the Trier Social Stress Test — a validated psychosocial stressor — found that a combination of 400 mg PS and 400 mg phosphatidic acid normalized the ACTH and cortisol response specifically in chronically stressed subjects, while having minimal effect in those with low baseline stress. This selectivity is clinically important: PS appears to exert its greatest benefit where it is most needed.
For BHRT providers, PS deserves particular attention in perimenopausal and postmenopausal women whose estrogen decline has already compromised HPAaxis resilience. Estrogen plays a regulatory role in cortisol feedback sensitivity, and its loss often unmasks or amplifies underlying adrenal dysregulation. Patients who describe sleep disruption, nighttime wakefulness with racing thoughts, abdominal weight gain, and emotional reactivity disproportionate to life circumstances are strong candidates for PS support alongside their hormone protocol. PS does not replace progesterone or estrogen in regulating the stress axis, but it can meaningfully reduce the cortisol burden during the transition period and beyond.
Clinical Note (Dosing)
The evidence-supported dosing range for cortisol modulation is 400–800 mg/day, taken in divided doses with meals to minimize GI discomfort. Soy-derived PS is the current standard formulation, as bovine cortex-derived PS is no longer used due to safety concerns. For patients with primarily sleep and nighttime cortisol dysregulation, dosing PS in the late afternoon or evening may be advantageous. A PS-phosphatidic acid complex (PAS) is available and may offer enhanced HPA axis normalization based on the Trier Social Stress Test trial data. For cognitive support applications, lower doses of 100–300 mg/day have been studied and are appropriate for patients where the primary indication is brain health rather than adrenal modulation. Pattern-matched cortisol testing — 4-point salivary or dried urine — should guide both the decision to use PS and the monitoring of outcomes.
Safety Considerations
Phosphatidylserine has an excellent safety profile and is generally well tolerated across the studied dosage ranges. The most commonly reported adverse effect is mild gastrointestinal upset, which is largely avoided by taking PS with food. There are no documented cases of PS inducing HPA axis suppression or adrenal insufficiency, and it is not associated with hepatotoxicity. PS has mild anticoagulant properties and should be used with caution in patients taking warfarin, clopidogrel, or other anticoagulant or antiplatelet agents; clinical significance at typical supplemental doses is uncertain, but the interaction warrants discussion. PS should be avoided or used cautiously in the perioperative period. Safety data in pregnancy and lactation is insufficient; use is not recommended in these populations. As with all supplements in the BHRT context, PS is an adjunct that complements rather than replaces appropriately tested and dosed hormone therapy.
Key References
- Monteleone P, et al. Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharmacol. 1992;42(4):385–388.
- Fahey TD, Pearl MS. The hormonal and perceptive effects of phosphatidylserine administration during two weeks of resistive exercise-induced overtraining. Biol Sport. 1998;15:135–144.
- Hellhammer J, et al. A soy-based phosphatidylserine/phosphatidic acid complex (PAS) normalizes the stress reactivity of hypothalamus-pituitary-adrenal axis in chronically stressed male subjects: a randomized, placebo-controlled study. Lipids Health Dis. 2014;13:121.
- Starks MA, et al. The effects of phosphatidylserine on endocrine response to moderate intensity exercise. J Int Soc Sports Nutr. 2008;5:11.
- White D. Hormones and HRT Prescribers Manual, 2nd Edition. BHRT Training Academy. 2025
